Shanghai-based Cryofocus Biotechnology Co., Ltd. (HKG: 6922) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its cryotherapy equipment, which supports its innovative frozen adhesion treatment system.
The cryotherapy equipment comprises a main unit, a foot switch, and an exhaust pipe, and is designed to work in conjunction with a disposable cryoprobe to create a comprehensive cryoadhesive therapy system. This system utilizes subcritical refrigeration technology and pressure-controlled heat transfer technology to enable rapid cryoadhesive treatments. The frozen adhesion treatment system is intended for the cryoremoval of foreign bodies, mucus, blood clots, and necrotic tissues in the airways, and is also applicable for frozen biopsies of bronchial and lung tissues.- Flcube.com
